Personalized briefing
Discovery of the day · Neurology
Plasma p‐tau217 detects Alzheimer’s disease co‐pathology in cerebral amyloid angiopathy: Comparison to CSF biomarkers in the ANGMAR cohort
Dear Kelly M Leyden, this is your personalized scientific intelligence briefing — curated for your work in Neurology.
Key finding
Medicine · Neurology
Discovery of the day
Plasma p-tau217 demonstrates high diagnostic accuracy for identifying Alzheimer’s disease co-pathology in patients with cerebral amyloid angiopathy (CAA), achieving an AUC of 0.920 in a cohort of 231 participants. The study found that predefined plasma p-tau217 cut-offs (≥0.27 pg/mL and ≥0.34 pg/mL) reliably discriminated CAA patients with and without AD co-pathology, and that p-tau217 levels showed no association with MRI markers of CAA burden, supporting its specificity for AD-related pathology. These findings reinforce the clinical actionability of plasma p-tau217 as a blood-based biomarker for distinguishing mixed vascular-neurodegenerative phenotypes, directly aligning with your focus on translating proteomic biomarkers into diagnostic assays that correlate with multimodal imaging and clinical data in neurodegenerative disease.
Novelty
88%
Rigor
92%
Significance
91%
Validity
90%
Clarity
93%
Advertisement
GroupRFQ — join group deals on lab & medical equipment. Pool orders, unlock volume pricing. See open deals →
Your briefing is personalized based on your selected fields, keywords, and research interests.
